The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 563-568

  Djerf Severinsson, Emelie A ^a   Trinks, Cecilia ^a   Gréen, Henrik ^a   Abdiu, Avni ^b   Hallbeck, Anna Lotta ^a,c   Stål, Olle ^a   Walz, Thomas M ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Centre of Surgery and Oncology   (Sweden)

Author keywords

Apoptosis; Canertinib; ErbB receptor; Malignant melanoma; Tyrosine kinase inhibitor

Indexed keywords

CAMPTOTHECIN; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL COUNT; CELL CYCLE G1 PHASE; CELL DIVISION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; STAT3 TRANSCRIPTION FACTOR;

MUS MUSCULUS;

EID: 80054882376     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.118     Document Type: Article

References (26)

1. Burton R.C. Malignant melanoma in the year 2000. CA Cancer J. Clin. 2000, 50:209-213.
2. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19:3635-3648.
3. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004, 122:337-341.
4. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
5. Flaherty K. Signal transduction inhibitors in advanced melanoma. American Society of Clinical Ocology 2006, 551-553.
6. Wellbrock C., Ogilvie L., Hedley D., et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004, 64:2338-2342.
7. Haluska F., Pemberton T., Ibrahim N., et al. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin. Oncol. 2007, 34:546-554.
8. Lazar-Molnar E., Hegyesi H., Toth S., et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554.
9. Sparrow L.E., Heenan P.J. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J. Dermatol. 1999, 40:19-24.
10. Rakosy Z., Vizkeleti L., Ecsedi S., et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int. J. Cancer 2007, 121:1729-1737.
11. Reschke M., Mihic-Probst D., van der Horst E.H., et al. HER3 is a determinant for poor prognosis in melanoma. Clin. Cancer Res. 2008, 14:5188-5197.
12. Kluger H.M., DiVito K., Berger A.J., et al. Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study. Melanoma Res. 2004, 14:207-210.
13. Prickett T.D., Agrawal N.S., Wei X., et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1134.
14. Djerf E.A., Trinks C., Abdiu A., et al. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib. Melanoma Res. 2009, 19:156-166.
15. Vindelov L.L., Christensen I.J., Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983, 3:323-327.
16. Geran R.I., Greenberg N.H., Macdonald M.M., et al. Protocols for screening chemical agents and natural products against animal tumours and other biological systems. Cancer Chemother. Rep. 1972, 3:1-103.
17. Nyati M.K., Maheshwari D., Hanasoge S., et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res. 2004, 10:691-700.
18. Hughes D.P., Thomas D.G., Giordano T.J., et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr. Blood Cancer 2006, 46:614-623.
19. Nelson J.M., Fry D.W. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem. 2001, 276:14842-14847.
20. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
21. Soltoff S.P., Carraway K.L., Prigent S.A., et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell Biol. 1994, 14:3550-3558.
22. Ako E., Yamashita Y., Ohira M., et al. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol. Rep. 2007, 17:887-893.
23. Niu G., Bowman T., Huang M., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21:7001-7010.
24. Rajput A., Koterba A.P., Kreisberg J.I., et al. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res. 2007, 67:665-673.
25. Slichenmyer W.J., Elliott W.L., Fry D.W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 2001, 28:80-85.
26. Richards K.N., Zweidler-McKay P.A., Van Roy N., et al. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 2010, 116:3233-3243.